Key facts
- Accipiter Biosciences’s last known valuation is $22.0M (Nov 2025).
- It has raised $13.6M across 2 recorded rounds; the latest was Early Stage VC ($13.6M) in May 2024.
- Notable investors include Creative Destruction Lab, Alexandria Venture Investments, Cercano Management, Argonautic Ventures, WRF Capital — 9 tracked in total.
- Accipiter Biosciences has filed 3 Form Ds with the SEC since 2023, most recently Sep 2025 ($13.6M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Accipiter Biosciences
Funding rounds
2 roundsAbout Accipiter Biosciences
Developer of a biotechnology platform designed to engineer de novo biologics for the treatment of complex diseases. The company offers computationally designed multifunctional proteins that combine multiple mechanisms within a single molecule, enabling biopharmaceutical companies and healthcare providers to develop therapies with improved safety, effectiveness, and patient convenience.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2023
- Employees
- 18
- Website
- accipiterbio.com/
- Ownership
- Privately Held (backing)
Accipiter Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accipiter Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accipiter Biosciences in its N-PORT filings yet. We sweep new filings monthly.